Suven (SUVENPHAR) | Stock Overview & Key Data
Suven Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,360.00 on December 2, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Suven
SUVENPHAR
|
412.87B Large-cap | 6.42% | 7.30% | -9.89% | 2.86% | 2.86% | 32.02% | 132.38% | 270.69% | 643.80% | 643.80% | 643.80% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Torrent
TORNTPHARM
|
1.39T Large-cap | 2.12% | 2.23% | 5.56% | 19.07% | 17.04% | 40.54% | 146.00% | 215.51% | 578.42% | 2,737.14% | 10,046.95% |
|
Cipla
CIPLA
|
1.06T Large-cap | -0.42% | -3.49% | 6.32% | -8.35% | -7.92% | -7.69% | 38.10% | 44.59% | 185.62% | 323.08% | 558.95% |
|
Mankind Pharma
MANKIND
|
946.57B Large-cap | 0.97% | -4.90% | 13.63% | 11.17% | 9.96% | -0.01% | 46.65% | 70.76% | 70.76% | 70.76% | 70.76% |
Ownership & Short Interest
Calculate Your Suven Investment Returns
Long-Term Investment Performance Analysis
Suven stock price in Mar 2020 was ₹145.65, A ₹1,000.00 lump sum investment in Suven made 5 years ago would be worth approximately ₹7,438.04 today, representing a exceptional return of 643.80%. This translates to an annualized return (CAGR) of 45.43%.
5 Years 4 Months Investment Scenario (Mar 2020 - Jul 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is SUVENPHAR's 52-week high and low?
- In the last 52 weeks, Suven reached a high of ₹1,360.00 (on December 2, 2024) and a low of ₹815.05 (on July 22, 2024).
- What is the market cap and P/E ratio for SUVENPHAR?
- Curious about Suven's size and valuation? Its market capitalization stands at 412.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is 99.01, and the forward P/E (looking ahead) is 57.20.
- Does SUVENPHAR pay dividends? If so, what's the yield?
- As for dividends, Suven isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Suven's main competitors or similar companies to consider before investing?
When looking at Suven, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Torrent
TORNTPHARM1.39T Healthcare Drug Manufacturers - Specialty & Generic 40.54% 146.00% Cipla
CIPLA1.06T Healthcare Drug Manufacturers - Specialty & Generic -7.69% 38.10% Mankind Pharma
MANKIND946.57B Healthcare Drug Manufacturers - Specialty & Generic -0.01% 46.65% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Suven Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Suven's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.38%, the Debt to Equity ratio from the most recent quarter is 1.95, and its Gross Profit Margin stands at 66.67%.
- What is the recent revenue and earnings growth for SUVENPHAR?
- Looking at Suven's growth, its revenue over the trailing twelve months (TTM) was INR10B. Compared to the same quarter last year (YoY), quarterly revenue grew by 39.70%, and quarterly earnings saw a YoY growth of 77.30%.
- How much of SUVENPHAR stock is held by insiders and institutions?
- Wondering who owns Suven stock? Company insiders (like executives and directors) hold about 73.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 14.76%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.